Pharmacokinetics and biodistribution of nanoparticles
Pharmacokinetics and biodistribution of nanoparticles
复制标题
DOI：
10.1021/mp800049w
复制
发表时间：
2008-07-01
影响因子：
4.9
通讯作者：
Huang, Leaf
中科院分区：
文献类型：
--
作者：
Li, Shyh-Dar;Huang, Leaf
纳米颗粒显示出其改善具有窄治疗窗口或低生物利用度的药物（例如抗癌药物和基于核酸的药物）的功效的前景。纳米颗粒的药代动力学（PK）和组织分布在很大程度上决定了其治疗效果和毒性。纳米颗粒的化学和物理性质，包括尺寸、表面电荷和表面化学，是决定其PK和生物分布的重要因素。还讨论了影响药物生物利用度的细胞内化后纳米颗粒的细胞内命运。提出了克服细胞内递送和药物释放障碍的策略。最后，未来的发展方向，提高PK的纳米粒子和前景在该领域进行了讨论。
Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity. Chemical and physical properties of the nanoparticles, including size, surface charge, and surface chemistry, are important factors that determine their PK and biodistribution. The intracellular fate of the nanoparticles after cellular internalization that affects the drug bioavailability is also discussed. Strategies for overcoming barriers for intracellular delivery and drug release are presented. Finally, future directions for improving the PK of nanoparticles and perspectives in the field are discussed.